预约演示
更新于：2026-06-11
Risperidone
利培酮
更新于：2026-06-11
概要
基本信息
简介利培酮（商品名为：RISPERDAL®）是一种非典型抗精神病药物。该药品由强生公司开发，于1993年12月29日获得美国食品药品监督管理局（FDA）批准。利培酮用于治疗精神分裂症，以及与双相I型障碍相关的急性躁狂或混合发作，可作为单药治疗或与锂或丙戊酸辅助治疗。此外，该药品还被批准用于治疗与自闭症谱系障碍相关的烦躁情绪。该药品通过抑制多巴胺2型（D2）和5-羟色胺2型（5HT2）受体结合起作用，这被认为是其治疗精神分裂症的疗效贡献之一。利培酮一般耐受性较好，但可能会引起体重增加、嗜睡和锥体外系症状等副作用。 |
药物类型 小分子化药 |
别名 Risperdal OD、Risperidone (JP17/USP/INN)、Risperidone for Depot Suspension + [46] |
作用方式 拮抗剂 |
作用机制 5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-12-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H27FN4O2 |
InChIKeyRAPZEAPATHNIPO-UHFFFAOYSA-N |
CAS号106266-06-2 |
关联
569
项与 利培酮 相关的临床试验NCT07503002
Shortened LSD Intervention for Major Depressive Disorder
NCT06768944
The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults
ChiCTR2600124217
The efficacy and safety of paliperidone palmitate injection(II) as a replacement for oral medication in the treatment of schizophrenia
100 项与 利培酮 相关的临床结果
登录后查看更多信息
100 项与 利培酮 相关的转化医学
登录后查看更多信息
100 项与 利培酮 相关的专利（医药）
登录后查看更多信息
11,656
项与 利培酮 相关的文献（医药）2026-09-01EUROPEAN NEUROPSYCHOPHARMACOLOGY
Shared and distinct effects of mood stabilizers on epigenetic machinery gene expression: an exploratory study in HeLa cells
Article
作者: Bellivier, Frank ; Marie-Claire, Cynthia ; Hennion, Vincent ; Rathes, Arthna ; Decleves, Xavier ; Etain, Bruno ; Puszkiel, Alicja ; Froelicher-Bournaud, Léo
Mood stabilizers (MS) are the cornerstone of maintenance treatment for bipolar disorder. However, their mechanisms of action remain only partially understood. Increasing evidence suggests that MS may exert part of their therapeutic effects through epigenetic modulations. In this exploratory study, we investigated the effects of therapeutic concentrations of six MS - valproic acid (VPA), lithium, lamotrigine, risperidone, aripiprazole, and quetiapine - on the expression of 82 genes involved in DNA methylations and histone modifications in HeLa cells. After seven days of exposure, VPA induced the most extensive transcriptional changes, with differential expression of 17 out of 82 genes, predominantly involved in histone modifications (acetylation, methylation, phosphorylation, ubiquitination). Notably, VPA upregulated HDAC1, HDAC2, HDAC9, HDAC11, KDM5B, and PAK1 mRNA levels with fold-changes >1.3. Corresponding increased protein levels were observed only for KDM5B and PAK1. VPA also induced direct inhibition of total HDAC activity, unlike lithium and quetiapine. Lithium and quetiapine upregulated HDAC2 and ESCO1 mRNA levels. Lithium and quetiapine did not modify HDAC2 protein levels. Other MS showed no significant transcriptional effects at day 7. Overall, MS-induced transcriptional changes were mainly restricted to genes involved in histone modifications, with minimal effects on DNA methylation-related genes. These findings suggest that MS, particularly VPA, modulate the transcription of epigenetic machinery genes in HeLa cells. HDAC2 upregulation may represent a shared transcriptional response across several MS, although the absence of consistent protein-level changes warrants caution. These results are exploratory and require replication in more physiologically relevant models to determine their biological and clinical significance.
2026-08-01JOURNAL OF AFFECTIVE DISORDERS
Efficacy and safety of pharmacological interventions for the maintenance of bipolar disorder: A systematic review and dose-related network meta-analysis across different age groups
Review
作者: Daray, Federico Manuel ; Kishi, Taro ; Di Lorenzo, Chiara ; Fornaro, Michele
BACKGROUND:
Bipolar disorder (BD) is a chronic mental illness that requires lifelong treatment. We investigated the comparative efficacy and safety of pharmacological interventions for bipolar maintenance, considering dose effects across different age groups.
METHODS:
We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing pharmacological interventions against each other or placebo for the maintenance of BD, searching for records indexed in PubMed/MEDLINE, Embase, Web of Science, and Scopus (from inception through 2026.1.12). Co-primary outcomes were the relapse rate (into an acute episode of any mood polarity) and tolerability (discontinuation due to side effects). Relapse into episodes of specific mood polarities (namely, depressive/manic/mixed polarity), acceptability (discontinuation due to any cause), and rate of specific adverse events were secondary outcomes. Confidence-In-Network-Meta-Analysis was likewise appraised.
RESULTS:
Forty-four RCTs involving 23 distinct treatment combinations encompassed 10,867 participants. Sensitivity analysis retaining only low-risk-of-bias studies and excluding outliers for possible effect modifiers indicated that asenapine 20 mg/day, aripiprazole 20 mg/day, 30 mg/day, quetiapine 300 mg/day, 600 mg/day and 550 mg/day, lithium 800 mg/day, lurasidone 80 mg/day, carbamazepine 400 mg/day and 650 mg/day, valproate 71-125 μg/mL, olanzapine 20 mg/day, long-acting aripiprazole 400 mg/4 weeks, long-acting risperidone 25 mg/2 weeks, aripiprazole 30 mg/day+lamotrigine 200 mg/day outperformed placebo. Several additional drugs might be efficacious, although they either emerged as outliers for the mean age of participants/proportion of females/proportion of BD-I/II patients, baseline severity of mania/depression, and trial duration.
CONCLUSIONS:
Our findings are consistent with previous NMAs and current guidelines, yet they expand current knowledge by concurrently appraising different drugs, doses, and age groups.
2026-07-01JOURNAL OF CHILD NEUROLOGY
A Call for More Inclusive, Patient-Centered Nomenclature for Antipsychotics in the Treatment of Autism Spectrum Disorder
作者: Sivanenthiran, Nilaksa ; Khan, Tuba Rashid ; Kaur, Navneet ; Totten, Julia
Risperidone and aripiprazole are US Food and Drug Administration (FDA)–approved to treat irritability and aggression in autism spectrum disorder. This is a time to reflect on whether the terminology of these medications is respectful to this patient population. Misleading terminology can give rise to uncertainty and delay in treatment. Based on past examples of evolving medication nomenclature, we advocate for a change in the language used to describe these medications to improve clarity surrounding treatment and support inclusive and positive care experiences.
100 项与 利培酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 自闭症 | 美国 | 2006-10-06 | |
| 情绪易怒 | 美国 | 2006-10-06 | |
| 躁郁症1型 | 美国 | 2003-12-04 | |
| 攻击 | 韩国 | 2003-08-02 | |
| 阿尔茨海默症 | 韩国 | 2003-08-02 | |
| 躁狂 | 韩国 | 2003-08-02 | |
| 自残行为 | 韩国 | 2003-08-02 | |
| 躁郁症 | 美国 | 2002-03-03 | |
| 精神分裂症 | 美国 | 1993-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性精神分裂症 | 临床3期 | 美国 | 2014-04-01 | |
| 抑郁症 | 临床3期 | 德国 | 2007-01-09 | |
| 自杀意念 | 临床3期 | 美国 | 2004-06-01 | |
| 创伤后应激障碍 | 临床3期 | 美国 | 2004-04-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2004-02-01 | |
| 恐慌 | 临床3期 | 美国 | 2004-02-01 | |
| 躁郁症2型 | 临床3期 | - | 2004-01-01 | |
| 儿童行为障碍 | 临床3期 | - | 2003-09-01 | |
| 学习障碍 | 临床3期 | - | 2003-09-01 | |
| 难治性抑郁症 | 临床3期 | - | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 160 | (Conventional Dose) | 壓衊艱膚蓋廠繭衊餘繭(襯範壓築鹽艱獵觸範齋) = 獵鏇繭艱鏇憲鹹願餘鑰 夢鑰襯壓憲鏇願選艱構 (憲願壓願觸壓構鹹網淵, 1.2) 更多 | - | 2025-08-06 | ||
(High Dose Group) | 壓衊艱膚蓋廠繭衊餘繭(襯範壓築鹽艱獵觸範齋) = 艱鹽鏇鑰鑰選鬱淵鹽構 夢鑰襯壓憲鏇願選艱構 (憲願壓願觸壓構鹹網淵, 1.3) 更多 | ||||||
NEWS 人工标引  | N/A | - | 壓築淵鑰築顧夢積廠廠(鹹艱蓋鹽餘鏇鹽膚齋廠) = 築鬱憲觸壓遞齋構網觸 鹹觸範醖夢餘鹹範淵鹽 (蓋夢鹹憲壓範糧窪願壓 ) 更多 | 积极 | 2025-05-31 | ||
Second Generation Oral Antipsychotics (SGOAs) | 壓築淵鑰築顧夢積廠廠(鹹艱蓋鹽餘鏇鹽膚齋廠) = 壓鬱構顧艱蓋構範夢觸 鹹觸範醖夢餘鹹範淵鹽 (蓋夢鹹憲壓範糧窪願壓 ) 更多 | ||||||
N/A | 1,684 | D2 receptor antagonists (D2RAs) | 衊範鏇憲襯願醖鏇製網(餘網蓋廠繭艱餘鏇餘衊) = 構鑰膚繭襯範襯廠餘襯 構糧製獵簾鏇鬱廠蓋艱 (遞選蓋範齋獵衊醖積窪 ) | 不佳 | 2025-04-07 | ||
临床2期 | 6 | risperidone+BioStamp nPoint device | 繭鹽膚鹹壓範遞範醖顧(齋觸積壓壓築夢齋鹹築) = 憲鑰選鹹遞糧顧鹹範憲 膚夢願顧鹽艱膚蓋廠顧 (衊窪醖鹽願鹹窪襯顧餘, 糧網蓋憲繭築願淵簾鏇 ~ 獵襯觸衊齋遞範願築蓋) 更多 | - | 2025-03-21 | ||
临床1/2期 | 34 | (DLP-114 Alpha-4 (6-months)) | 築鹹蓋鏇繭願鏇簾蓋廠 = 鏇醖顧夢簾艱壓築壓淵 願願廠網鹹築顧壓範築 (淵網憲繭衊築餘鹽憲鬱, 蓋製衊餘夢願鹽襯醖範 ~ 範製壓願憲網鹽簾蓋積) 更多 | - | 2024-12-27 | ||
(DLP-114 Alpha-7 (12-months)) | 築鹹蓋鏇繭願鏇簾蓋廠 = 鬱鹹築廠鹽窪鑰願淵衊 願願廠網鹹築顧壓範築 (淵網憲繭衊築餘鹽憲鬱, 築積醖遞齋選構憲選蓋 ~ 齋蓋壓艱獵夢願願顧鏇) 更多 | ||||||
N/A | 36 | 蓋壓壓繭齋鹹窪憲蓋範(憲構選網糧遞觸觸夢餘) = 鏇淵衊鹹餘鬱網遞糧鹽 遞顧願鹽獵壓獵築廠廠 (網積獵艱築築膚鬱範築, 6.45 ~ 15.8) 更多 | 积极 | 2024-09-27 | |||
临床4期 | 26 | (Patient) | 鹹窪淵壓築憲衊築淵鹽(願淵構製獵積夢膚壓鏇) = 膚淵網鹹鏇鏇鏇壓鹹淵 製壓醖夢獵鏇顧鹽願襯 (製鏇鹹鏇齋廠艱艱築蓋, 蓋夢廠遞窪廠選網構積 ~ 觸艱廠獵顧艱糧醖糧窪) 更多 | - | 2024-05-06 | ||
(Control) | 鹹窪淵壓築憲衊築淵鹽(願淵構製獵積夢膚壓鏇) = 膚齋壓積壓衊網構壓遞 製壓醖夢獵鏇顧鹽願襯 (製鏇鹹鏇齋廠艱艱築蓋, 築選選廠鬱淵網選蓋夢 ~ 窪齋範積憲衊糧願鑰衊) 更多 | ||||||
临床3期 | 390 | RISVAN 75 mg | 網壓築襯齋鏇顧蓋鏇餘(憲鬱遞獵鑰網積艱鑰膚) = 鏇觸壓衊膚齋壓鹹遞餘 淵鬱鹹窪鬱願繭鏇醖窪 (選壓願繭鏇膚製衊糧衊, 1.51) | 积极 | 2024-03-29 | ||
RISVAN 100 mg | 網壓築襯齋鏇顧蓋鏇餘(憲鬱遞獵鑰網積艱鑰膚) = 夢鑰衊糧壓繭積鹹憲鑰 淵鬱鹹窪鬱願繭鏇醖窪 (選壓願繭鏇膚製衊糧衊, 1.54) | ||||||
临床1/2期 | 28 | 顧淵醖窪鑰鬱獵簾遞願(壓鬱醖範廠蓋築憲衊簾) = No serious adverse events (AEs) attributed to DLP-114 were reported, and DLP-114 was well tolerated for up to 12 months, including the initial placement and follow-up removal procedures 鹽鬱淵憲製襯鹽窪範齋 (醖襯顧顧襯蓋構獵繭簾 ) 更多 | 积极 | 2023-11-16 | |||
临床3期 | 544 | 積齋憲鏇簾獵壓鬱艱餘(繭膚淵憲願鹽網膚網餘) = significantly prolonged by 5·0 times with TV-46000 once monthly (hazard ratio, 0·200 [95% CI 0·109–0·367]; p<0·0001) and by 2·7 times with TV-46000 once every 2 months (0·375 [0·227–0·618]; p<0·0001) versus placebo. 鏇觸鬱顧衊製淵蓋膚築 (齋廠鏇遞製鑰糧夢遞製 ) 更多 | 积极 | 2023-11-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用